A baby girl who was close to dying from cancer has been rescued by a cell therapy envisioned as a “one size fits all” treatment that had never been tested in people, doctors reported on Thursday.
The development is significant because it indicates that cell therapies, which represent an exciting new front in the battle against cancer, might not have to be customized for each patient, saving time and money.
It also represents one of the first times that a novel “genome editing” technique has been used to treat someone. The therapy was developed by Cellectis, a French biotechnology company.
But it is hard to say much based on one patient. Also, the girl has been in remission for only a few months, too little time to say she has been cured, said Waseem Qasim, one of the doctors who treated her at the Great Ormond Street Hospital in London.
Still, the girl’s doctors “think it is a remarkable outcome,” because she had not been helped by conventional therapies, Dr. Qasim said in an interview.
Cancer doctors have been electrified by a new approach that involves genetically altering patients’ T cells, the soldiers of the immune system, so that they can better attack cancers.
Some patients with certain blood cancers have made remarkable recoveries. They include a girl who received a treatment developed at the University of Pennsylvania and now licensed to Novartis. Other companies pursuing this approach, often called CAR-T, including Juno Therapeutics and Kite Pharma, have achieved large stock market valuations.
But the first versions of their experimental therapies require extracting the T cells from the patient, shipping them to a manufacturing plant where they can be altered, then sending them back and putting them back into the patient, something that will be logistically challenging and costly for thousands of patients. Cellectis’s therapy is meant to work for any patient with a particular type of leukemia.
Cellectis’s American depositary receipts soared 18 percent on Thursday, while shares of Juno fell 7 percent and those of Kite dipped 2 percent.
Still the personalized treatments could reach the market in the next couple of years, long before Cellectis’s treatment, which will not even enter early-stage clinical trials until next year.
The case of the girl’s recovery will be presented to doctors next month at the annual meeting of the American Society of Hematology in Orlando, Fla. But abstracts for that conference were made public Thursday, and the hospital publicized the case.
The girl, Layla Richards of London, had acute lymphoblastic leukemia. Doctors tried the usual chemotherapy, a bone marrow transplant and a new type of biotech drug, but nothing worked. Layla did not have enough T cells to allow doctors to extract them and make a personalized therapy.
Her parents, Ashleigh Richards and Lisa Foley, were counseled to consider palliative care to keep her comfortable until she died, Dr. Qasim said. But the parents were not willing to do that.
In what might be a lucky coincidence, the hospital was already manufacturing Cellectis’s cells in preparation for clinical trials. “We had them in our freezers,” Dr. Qasim said. He is also a professor at University College London, which worked with Cellectis on the treatment.
So, with permission from her parents and Cellectis, Layla became the first person to receive the treatment, on what is sometimes called a compassionate use basis.
The Latest on: Experimental therapies
via Google News
The Latest on: Experimental therapies
- UW Medicine, Fred Hutch test experimental antibody treatment used on Trump for COVID-19on October 10, 2020 at 1:43 am
Regeneron Pharmaceuticals' cocktail of two monoclonal antibodies was used to treat President Donald Trump for COVID-19.
- U.S. Expects 1 Million Doses of Covid Antibody Before 2021on October 9, 2020 at 10:57 am
The U.S. has already secured hundreds of thousands of doses of experimental antibody treatments for Covid-19 in anticipation of regulators authorizing their emergency use, federal health officials ...
- Trump praises experimental coronavirus antibody treatment; second debate called offon October 9, 2020 at 9:33 am
President Trump today said an experimental antibody cocktail he was given after catching coronavirus cured him.
- Veteran Beats COVID-19 After Experimental Therapyon October 9, 2020 at 4:35 am
Jim Warehime is a veteran of the Vietnam conflict and now COVID-19. He was on what seemed to be his deathbed when doctors turned to an experimental treatment, convalescent plasma therapy, and it ...
- Donald Trump calls catching COVID ‘blessing in disguise,’ touts experimental antibody treatment: 'I feel like perfect'on October 9, 2020 at 3:05 am
In a video released Wednesday, President Donald Trump talked up the benefits of an experimental antibody drug given to treat him for COVID.
- Medical Community Pushing Back On Regeneron Asking For Emergency Approval Of Experimental Coronavirus Treatmenton October 8, 2020 at 2:38 pm
After President Donald Trump claimed he was cured of COVID-19 by an experimental treatment, the company that makes it, Regeneron, asked the FDA for emergency approval late Wednesday night. The ...
- President Trump hails experimental COVID-19 treatment, says he's ready for rallieson October 8, 2020 at 12:59 pm
During a phone interview Thursday morning on Fox Business, the president said he thinks he's feeling at "the point where I’d love to do a rally tonight." ...
- Trump Touts Experimental Treatment As ‘Cure,’ Urges Emergency Use, Free Accesson October 8, 2020 at 10:21 am
The White House posted a five-minute video in which President Donald Trump talked about his experience with COVID-19 treatments, in particular praising Regeneron’s experimental therapeutic ...
- Trump hails experimental treatment for his virus recovery, without providing evidenceon October 8, 2020 at 7:51 am
President Donald Trump credited an experimental drug treatment with helping his recovery from Covid-19 and suggested his diagnosis could be a "blessing in disguise" in the nation's battle against the ...
- President Trump hails experimental treatment for his coronavirus recoveryon October 8, 2020 at 5:48 am
Questions continue to swirl about the trajectory of Trump's recovery and when he might be able to return to normal activities, including campaigning.
via Bing News